CYAD News and Press, Celyad SA From 04/01/21

MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the compan...

Celyad Oncology SA (CYAD) Q4 2020 Earnings Conference Call March 25, 2021 8:00 AM ET Company Participants Filippo Petti – Chief Executive Officer David Gilham – Chief Scientific Officer, Frederic Lehmann – Vice President-Global Clinical Development & Medical Affairs, ...

Celyad Oncology (CYAD): FY GAAP EPS of -€1.23.Revenue of €5K (-16.7% Y/Y)Cash position of €17.2 million ($21.2 million) as of December 31, 2020.Press Release For further details see: Celyad Oncology reports FY results

No safety concerns or evidence of Graft-versus-Host disease reported from first dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); enrollment in second dose cohort initiate...

MONT-SAINT-GUIBERT, Belgium, March 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Compan...

The following slide deck was published by Celyad Oncology SA in conjunction with this event. For further details see: Celyad Oncology (CYAD) Investor Presentation - Slideshow

MONT-SAINT-GUIBERT, Belgium, March 01, 2021 (GLOBE NEWSWIRE) -- Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for ca...

MONT-SAINT-GUIBERT, Belgium, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company...

Celyad Oncology (CYAD) rises 8% in premarket on the heels of updated data from Phase 1 alloSHRINK trial evaluating CYAD-101, its allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR T candidate, administered concurrently with FOLFOX chemo...

Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the hig...